Your session is about to expire
← Back to Search
Nivolumab + Radium-223 for Prostate Cancer (Rad2Nivo Trial)
Rad2Nivo Trial Summary
This trial is testing a new safety drug in two phases. First, a small group of people will test it to make sure it's safe. If it is, then a larger group of people will use it.
Rad2Nivo Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRad2Nivo Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Rad2Nivo Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am using or will use effective birth control during and for 7 months after the study.You have had a very bad allergic reaction in the past to the study drug or any of its ingredients.My liver is functioning properly.My kidneys are functioning well enough for treatment.My prostate cancer was confirmed through a tissue examination.I have not received any live vaccines within the last 4 weeks.I have recovered from previous cancer treatment side effects, or they are minor and stable.I have another type of cancer, but it won't affect this trial's treatment.I have stopped taking certain medications as required before starting treatment.I have hepatitis B or C with a detectable virus level, or it's undetectable.My kidney function is within normal ranges.I am not on immunosuppressive drugs, except for low-dose or topical steroids.I am a man aged 18 or older.My prostate cancer has spread and is resistant to hormone therapy, but it hasn't spread to my internal organs.I do not have serious heart conditions such as recent heart attacks, unstable angina, severe heart failure, or dangerous arrhythmias.I can take care of myself but might not be able to do heavy physical work.My bilirubin levels are within normal range, or I have Gilbert's syndrome.My organs are functioning well.My testosterone levels are below 50 ng/dL.My doctor says my cancer has spread to my bones and is causing symptoms.
- Group 1: Treatment: all patients
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the total enrollment capacity for this medical experiment?
"Affirmative. Clinicaltrials.gov details indicate that this trial was launched on August 25 2020 and is currently seeking volunteers. 36 participants need to be enrolled at a single clinical site."
Are there any openings left for this clinical trial?
"Affirmative. As confirmed by clinicaltrials.gov, the medical study is still recruiting participants as of April 21st 2022; it was first advertised on August 25th 2020. The research project demands 36 volunteers from 1 site to partake in the trial."
Is this research unprecedented in its approach?
"Research surrounding Nivolumab began in 2012, when Ono Pharmaceutical Co. Ltd sponsored its initial study involving 659 patients. This led to the drug receiving Phase 1 and 2 approval, sparking a wave of clinical trials around the world with 723 active studies occurring across 2357 cities and 49 countries today."
In what medical scenarios is Nivolumab typically prescribed?
"Nivolumab has been found to have positive effects in treating malignant tumours, unresectable melanoma, and squamous cell carcinomas."
Can you please provide an overview of the prior research on Nivolumab?
"Currently, 723 trials are actively researching Nivolumab with 83 Phase 3 studies. The medication is being investigated in 40342 different areas of the globe, including Basel, BE."
What is the aim of this experiment?
"The primary objective of this medical trial, anticipated to last 30 months, is the assessment of nivolumab's safety when combined with Radium-223 in patients with metastatic castrate resistant prostate cancer. Additionally, researchers will evaluate radiographic progression-free survival according to PCWG3 criteria and PSA progression free survival using Prostate Cancer Working Group 3 (PCWG3). Lastly, there will be a correlation analysis between bone metabolism markers and clinical response."
Share this study with friends
Copy Link
Messenger